Should I buy Roivant Sciences (ROIV) stock or is it too late?

Roivant Sciences · Health Care · price $38

See the full Roivant Sciences (ROIV) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (52 calls tested). It aims for $42 (+12 %), call made on August 8, 2026, maturing on August 8, 2027 (20 d ago).

The 3 reliable analysts $42+12 %

The 2 other firms $40.50+7.8 %

How to read it: the 3 reliable firms are not filtered by optimism — 3 aim above the price, 0 below, hence their $42 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Roivant Sciences

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
HC Wainwright & Co.	80 %	+44.1 %	20	$41 +9%
JP Morgan	100 %	+32.8 %	6	$20 -47%
Cantor Fitzgerald	78 %	+21.8 %	9	$15 -60%
Goldman Sachs	40 %	+20.5 %	5	$33 -12%
Truist Securities	40 %	-7.0 %	5	$23 -39%
SVB Leerink	80 %	+74.6 %	5	—

In short — Should you invest in Roivant Sciences? Is it too late, still worth it? Analysts are overwhelmingly positive (100% buy, median target $41, i.e. +9%), and the most reliable on ROIV targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

100% of analysts rate it a buy (Buy consensus, 5 ratings) — a sign of market conviction.
Median price target $41, i.e. +9% from the current price ($38).
The most reliable firm on ROIV, Citigroup (100% hit rate, 3 scored calls), targets $46 (call made on August 10, 2026, maturing on August 10, 2027) (+22%) in its most recent call, and $16 (call made on September 2, 2025, maturing on September 2, 2026) (-57%) in the one coming due soonest.

⚠️ Reasons to hesitate

A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.
A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.

The analyst consensus on ROIV

Median target $41 (+9%) · 5 ratings · Buy consensus

Strong Buy00%

Buy5100%

Hold00%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Roivant Sciences now?

We won't decide for you. The facts: 100% of analysts rate it a buy, median target $41 (+9%), and Citigroup (most reliable on ROIV, 100%) targets $46. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Roivant Sciences?

Not according to analysts: the median target ($41) is still +9% above the current price ($38) (most reliable on ROIV: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Roivant Sciences still worth investing in?

It depends on the gap between the price ($38) and its estimated value: analysts target $41 on median (+9%), with 100% buys (most reliable on ROIV: Citigroup, 100%). Cross-check with their real reliability on ROIV and the cautions above. Information, not advice.

What's the main risk in buying ROIV?

A 12-month target is not a guaranteed path: the price can fall in the meantime.

→ Go deeper: the full Roivant Sciences profile (consensus, analyst reliability, price target, performance).